Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by G1945Von Feb 08, 2024 1:57pm
109 Views
Post# 35870519

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ENDPOINTS NEWS Jan 31, 2024

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ENDPOINTS NEWS Jan 31, 2024
BottomBroker wrote: How do you explain the share price since the move to the Nasdaq? It was at  $6-8 when first listed. 

SINCE then, Promis has:

 - received approval for an IND from the FDA
 - released postitive pre-clinical data 
 - started Phase 1 trials

Pretty good news, right?

Well, as everyone knows, the share price has gone nowhere but down - almost back to penny-stock status not too long ago - and now is just barely keeping its head above Nasdaq-delisting terrority.

I don't know about anyone else, but that doesn't make a whole lot of sense to me. 




The stock went from $8.14 on April 27, 2023, to:

On July 7, 2023, joined the Nasdaq $3.70

July 17, 2023, $6.19 (~ 14 million shares traded, the market in a "cash frenzy")

Delisted from TSX July 21, 2023, $4.55 ~ 130K shares traded

And continued dropping, now stands at $2.00

I just don't see any other explanation but the market dictates the price.



G1945V
<< Previous
Bullboard Posts
Next >>